# Sangamo Therapeutics, Inc.

> Sangamo Therapeutics is a clinical-stage genomic medicine company in Brisbane, California that engineers zinc finger proteins to switch genes on, off, or rewrite them. After three decades pioneering zinc finger technology, it is racing to bring its lead gene therapy ST-920 for Fabry disease to market while building a neurology pipeline aimed at crossing the blood-brain barrier - all under the pressure of a 2026 search for strategic alternatives.

- **Founded:** 1995
- **Headquarters:** Brisbane, California, United States
- **Founders:** Edward O. Lanphier II (Founder (former President & CEO))
- **Team size:** ~190 employees
- **Products:** ST-920 (isaralgagene civaparvovec), Zinc finger platform (ZFP), Neurology pipeline, Novel AAV capsid engineering
- **Notable:** Pioneered zinc finger nuclease genome editing years before CRISPR entered the mainstream., Advanced ST-920, a one-time gene therapy for Fabry disease, into a rolling FDA BLA under the Accelerated Approval Program., Demonstrated a positive mean annualized eGFR slope (~3.06 mL/min/1.73m2/yr) in 23 Fabry patients in the STAAR study, with ERT patients withdrawn and staying off treatment.

## Products & services

- **ST-920 (isaralgagene civaparvovec)** — Wholly owned investigational one-time AAV gene therapy for adults with Fabry disease, given without preconditioning. In Phase 1/2 STAAR it showed a positive mean eGFR slope and allowed enzyme-replacement-therapy patients to come off treatment; rolling BLA submission to the FDA under the Accelerated Approval Program initiated in late 2025.
- **Zinc finger platform (ZFP)** — Proprietary engineered zinc finger proteins used as nucleases (ZFNs) for editing and as transcription factors / epigenetic regulators (zinc finger repressors) to switch specific genes off or on without cutting DNA.
- **Neurology pipeline** — Genomic medicines aimed at the central nervous system, including programs for idiopathic small fiber neuropathy, chronic neuropathic pain (Nav1.7 gene repression), prion disease and tauopathies, built on blood-brain-barrier-penetrant AAV capsids.
- **Novel AAV capsid engineering** — Engineered, blood-brain-barrier-crossing AAV capsids designed to deliver genomic medicines intravenously to the brain - the delivery technology underpinning Sangamo's neurology partnerships.

## Achievements

- Pioneered zinc finger nuclease genome editing years before CRISPR entered the mainstream.
- Advanced ST-920, a one-time gene therapy for Fabry disease, into a rolling FDA BLA under the Accelerated Approval Program.
- Demonstrated a positive mean annualized eGFR slope (~3.06 mL/min/1.73m2/yr) in 23 Fabry patients in the STAAR study, with ERT patients withdrawn and staying off treatment.
- Engineered blood-brain-barrier-penetrant AAV capsids enabling intravenous delivery to the CNS.
- Secured large platform partnerships with Genentech, Pfizer, Astellas and others.

## Latest updates

- **2026-06** — Announced exploration of strategic alternatives, retaining Raymond James as financial advisor to maximize stakeholder value while advancing the pipeline.
- **2026-Q1** — Advanced the rolling BLA submission for ST-920 in Fabry disease and progressed the neurology pipeline; priced a $25M underwritten offering.
- **2025-12** — Initiated rolling BLA submission to the FDA for ST-920 in Fabry disease under the Accelerated Approval Program.
- **2025** — Received FDA clearance for its first neurology IND, targeting idiopathic small fiber neuropathy, with enrollment beginning mid-2025.

## Links

- Website: https://sangamo.com
- LinkedIn: https://www.linkedin.com/company/sangamo-therapeutics
- Twitter/X: https://twitter.com/sangamotx
- YouTube: https://www.youtube.com/c/SangamoTherapeutics
- Facebook: https://facebook.com/SangamoTx/

---

Profile page: https://yespress.io/sangamo-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-20